Enliven Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Enliven Therapeutics, Inc. (ELVN), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ELVN insiders buying or selling?
In the last 12 months, Enliven Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 35 sales ($77.0M) — net selling of $77.0M. Since March 2020, Trabud has recorded 231 Form 4 filings for ELVN: 28 buys ($127.8M) and 203 sells ($190.1M).
Source: SEC EDGAR Form 4
What stands out
- No Enliven Therapeutics, Inc. insider made an open-market purchase in the last 12 months; the 35 reported open-market sales totaled $77.0M.
Key Statistics (March 2020 – Oct 5, 2026)
Total Form 4 filings
231
SEC EDGAR
Insider filers
27
Insider buys (28)
$127.8M
Insider sells (203)
$190.1M
Insider sentiment
Net sellingNet insider flow of $62.3M in net selling since March 2020, and $77.0M in net selling over the last 12 months.
Recent ELVN insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Scott J. Garland | Director | Sale | 13.0K | $46.67 | $606.7K | SEC ↗ |
| Sep 21, 2026 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale | 6.0K | $50.35 | $303.0K | SEC ↗ |
| Sep 21, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale | 5.0K | $50.35 | $251.8K | SEC ↗ |
| Aug 19, 2026 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale | 6.0K | $58.58 | $352.6K | SEC ↗ |
| Aug 19, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale | 5.0K | $58.59 | $292.9K | SEC ↗ |
| Aug 7, 2026 | Mika K Derynck | Director | Sale | 158.8K | $60.21 | $9.6M | SEC ↗ |
| Jul 21, 2026 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale | 6.0K | $52.64 | $316.8K | SEC ↗ |
| Jul 21, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale | 5.0K | $52.67 | $263.4K | SEC ↗ |
| Jul 8, 2026 | Lori Anne Kunkel | Director | Sale | 10.0K | $50.49 | $504.9K | SEC ↗ |
| Jun 24, 2026 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 860.1K | $45.36 | $39.0M | SEC ↗ |
| Jun 22, 2026 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale | 6.0K | $43.80 | $263.6K | SEC ↗ |
| Jun 22, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale | 5.0K | $43.80 | $219.0K | SEC ↗ |
| Jun 17, 2026 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 281.4K | $45.02 | $12.7M | SEC ↗ |
| Jun 9, 2026 | Lori Anne Kunkel | Director | Sale | 10.0K | $34.54 | $345.4K | SEC ↗ |
| May 20, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale | 5.0K | $39.79 | $199.0K | SEC ↗ |
| Apr 22, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale | 5.0K | $47.67 | $238.4K | SEC ↗ |
| Mar 27, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale | 40.0K | $35.10 | $1.4M | SEC ↗ |
| Mar 19, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale | 5.0K | $27.76 | $138.8K | SEC ↗ |
| Mar 11, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale | 40.0K | $30.07 | $1.2M | SEC ↗ |
| Mar 10, 2026 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale | 10.0K | $29.58 | $295.8K | SEC ↗ |
| Feb 19, 2026 | Richard A. Heyman | Director | Sale | 1.2K | $26.18 | $32.2K | SEC ↗ |
| Feb 19, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale | 45.0K | $26.17 | $1.2M | SEC ↗ |
| Feb 10, 2026 | Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale | 5.0K | $29.04 | $145.2K | SEC ↗ |
| Jan 22, 2026 | Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale | 20.0K | $26.75 | $535.1K | SEC ↗ |
| Jan 22, 2026 | Richard A. Heyman | Director | Sale | 1.2K | $26.75 | $32.9K | SEC ↗ |
Showing the 25 most recent of 231 Form 4 filings for Enliven Therapeutics, Inc..
Most active ELVN insiders
- Benjamin Hohl40 filings
- Joseph P Lyssikatos36 filings
- Samuel Kintz32 filings
- Anish Patel26 filings
- Richard A. Heyman19 filings
Ask anything about ELVN insider activity
Use Trabud's AI agent to query Enliven Therapeutics, Inc.'s Form 4 history in plain English — "Show me ELVN CEO purchases this year" or compare it against any other ticker.
Open the AI agentELVN insider trading FAQ
Are Enliven Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Enliven Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 35 sales ($77.0M) — net selling of $77.0M. Since March 2020, Trabud has recorded 231 Form 4 filings for ELVN: 28 buys ($127.8M) and 203 sells ($190.1M). Over the full record that is net selling of $62.3M.
How many insiders trade ELVN stock?
27 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Enliven Therapeutics, Inc.. The most recent filing was accepted on Oct 5, 2026.
Where does Trabud get ELVN insider trading data?
All ELVN insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.